Compugen
Compugen is a pioneering cancer immunotherapy company utilizing advanced computational target discovery through its AI/ML-powered platform, Unigen™, to develop novel and first-in-class cancer treatments. With a focus on immuno-oncology, the company integrates deep scientific knowledge with innovative technology to identify new drug targets and develop therapies that expand treatment options for cancer patients. Its approach involves a flexible, continuous learning platform that combines multi-omics data, spatial transcriptomics, and human expertise to discover and validate novel immuno-oncology targets, aiming to bring first-in-class drugs to clinical development and improve patient outcomes.
Industries
Nr. of Employees
medium (51-250)
Products
Investigational monoclonal antibody targeting PVRIG (clinical-stage)
A clinical-stage monoclonal antibody developed to block the PVRIG immune-checkpoint pathway; advanced into early-phase clinical trials and evaluated as monotherapy and in combination with other checkpoint inhibitors.
Investigational monoclonal antibody targeting TIGIT (clinical-stage)
A clinical-stage antibody directed against the TIGIT immune-checkpoint pathway, evaluated alone and in combination with other checkpoint inhibitors.
PD-1/TIGIT bispecific antibody (partner-developed, clinical-stage)
A bispecific antibody format engaging PD-1 and TIGIT developed for enhanced co-operative binding and immune activation; advanced into late-stage clinical studies by a development partner.
Investigational monoclonal antibody targeting PVRIG (clinical-stage)
A clinical-stage monoclonal antibody developed to block the PVRIG immune-checkpoint pathway; advanced into early-phase clinical trials and evaluated as monotherapy and in combination with other checkpoint inhibitors.
Investigational monoclonal antibody targeting TIGIT (clinical-stage)
A clinical-stage antibody directed against the TIGIT immune-checkpoint pathway, evaluated alone and in combination with other checkpoint inhibitors.
PD-1/TIGIT bispecific antibody (partner-developed, clinical-stage)
A bispecific antibody format engaging PD-1 and TIGIT developed for enhanced co-operative binding and immune activation; advanced into late-stage clinical studies by a development partner.
Services
AI/ML-powered computational target discovery and biomarker identification
Discovery service that applies AI/ML algorithms to integrated multi-omics and single-cell/spatial datasets to generate and prioritize novel therapeutic targets and predictive biomarkers.
Translational validation and bioanalytical support
Preclinical and translational experimental validation services including MOA studies, bioassays, and biomarker assays to confirm computational predictions.
Clinical development and trial support (early-phase and combination studies)
Design and operational support for early-phase clinical trials and adaptive platform studies, including combination regimen evaluation and biomarker-driven designs.
AI/ML-powered computational target discovery and biomarker identification
Discovery service that applies AI/ML algorithms to integrated multi-omics and single-cell/spatial datasets to generate and prioritize novel therapeutic targets and predictive biomarkers.
Translational validation and bioanalytical support
Preclinical and translational experimental validation services including MOA studies, bioassays, and biomarker assays to confirm computational predictions.
Clinical development and trial support (early-phase and combination studies)
Design and operational support for early-phase clinical trials and adaptive platform studies, including combination regimen evaluation and biomarker-driven designs.
Expertise Areas
- Computational target discovery for immuno-oncology
- Multi-omics and single-cell spatial analysis
- Biomarker discovery and patient stratification
- Therapeutic antibody and multi-specific antibody development
Key Technologies
- Single-cell RNA sequencing
- Spatial transcriptomics
- Multi-omics integration
- AI/ML and deep learning predictive algorithms